Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 24-week Parallel-group Placebo-controlled Multicenter (Phase 2) Study of Anthocyanins in People at Risk for Dementia

NCT03419039 is registered in ClinicalTrials.gov with Helse Stavanger HF as lead sponsor.

NCT NCT03419039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03419039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 24-week Parallel-group Placebo-controlled Multicenter (Phase 2) Study of Anthocyanins in People at Risk for Dementia
Lead sponsor
Helse Stavanger HF
Phase
Not applicable
Overall status
Unknown status
Start date
January 5, 2018
Completion date
February 15, 2021
Enrollment
212 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, dementia, inflammation, mild cognitive impairment